Preventing Future Deaths from Medicines: Responses to Coroners’ Concerns in England and Wales

Robin E. Ferner (), Tohfa Ahmad, Zainab Babatunde and Anthony R. Cox
Additional contact information
Robin E. Ferner: West Midlands Centre for Adverse Drug Reactions
Tohfa Ahmad: West Midlands Centre for Adverse Drug Reactions
Zainab Babatunde: University of Birmingham
Anthony R. Cox: West Midlands Centre for Adverse Drug Reactions

Drug Safety, 2019, vol. 42, issue 3, No 9, 445-451

Abstract: Abstract Introduction Coroners inquire into sudden, unexpected, or unnatural deaths. We have previously established 99 cases (100 deaths) in England and Wales in which medicines or part of the medication process or both were mentioned in coroners’ ‘Regulation 28 Reports to Prevent Future Deaths’ (coroners’ reports). Objective We wished to see what responses were made by National Health Service (NHS) organizations and others to these 99 coroners’ reports. Methods Where possible, we identified the party or parties to whom these reports were addressed (names were occasionally redacted). We then sought responses, either from the UK judiciary website or by making requests to the addressee directly or, for NHS and government entities, under the Freedom of Information Act 2000. Responses were analysed by theme to indicate the steps taken to prevent future deaths. Results We were able to analyse one or more responses to 69/99 cases from 106 organizations. We analysed 201 separate actions proposed or taken to address the 160 concerns expressed by coroners. Staff education or training was the most common form of action taken (44/201). Some organisations made changes in process (24/201) or policy (17/201), and some felt existing policies were sufficient to address some concerns (22/201). Conclusions Coroners’ concerns are often of national importance but are not currently shared nationally. Only a minority of responses to coroners’ reports concerning medicines are in the public domain. Processes for auditing responses and assessing their effectiveness are opaque. Few of the responses appear to provide robust and generally applicable ways to prevent future deaths.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-018-0738-z Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:3:d:10.1007_s40264-018-0738-z

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-018-0738-z

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().